Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With CAP Including COVID-19 Pneumonia.

NCT05531149 is registered in ClinicalTrials.gov with Biotest as lead sponsor.

NCT NCT05531149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05531149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With CAP Including COVID-19 Pneumonia.
Lead sponsor
Biotest
Phase
Phase 3
Overall status
Terminated
Start date
December 22, 2022
Completion date
May 5, 2025
Enrollment
107 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, bacterial pneumonia, community-acquired pneumonia, covid-19, fungal pneumonia, pneumonia, respiratory infection, viral pneumonia